Business Context and Reporting Period
Cognition Therapeutics, Inc. (CGTX), a Delaware corporation and emerging growth company, filed this Form 8-K to report the results of its Annual Meeting of Stockholders held on June 17, 2026. The meeting was conducted virtually.
Key Financial Metrics
This filing is a current report regarding corporate governance events and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes
No material financial changes are reported in this filing. The document details the outcome of stockholder votes on director elections and auditor ratification.
Guidance, Outlook, and Management Commentary
The filing contains no forward-looking guidance, management commentary on operations, or discussion of risks and contingencies beyond the standard disclosure of voting results.
Important Facts for Investors
- Director Elections: Stockholders elected Aaron Fletcher, Ph.D., and Lisa Ricciardi as Class II directors to serve until the 2029 Annual Meeting.
- Voting Results (Proposal 1):
- Aaron Fletcher, Ph.D.: 15,093,537 votes For; 680,677 votes Withheld; 34,035,661 Broker Non-Votes.
- Lisa Ricciardi: 15,094,238 votes For; 679,976 votes Withheld; 34,035,661 Broker Non-Votes.
- Auditor Ratification: Stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the 2026 fiscal year.
- Voting Results (Proposal 2): 49,039,407 votes For; 126,951 votes Against; 643,517 Abstentions; 0 Broker Non-Votes.